18th week of 2015 patent applcation highlights part 58 |
Patent application number | Title | Published |
20150119396 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS - The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. | 2015-04-30 |
20150119397 | HISTONE DEMETHYLASE INHIBITORS - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 2015-04-30 |
20150119398 | FORM 2 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-- YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE - The present invention provides the Form 2 crystalline polymorph of 7-(ieri-Butyl-d9)-3-(2,5-difluorophenyl)-6((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine. The polymorph disclosed herein is characterized according to one or more of (a) powder X-ray diffraction data (“XRPD”); (b) differential scanning calorimetry (“DSC”); (c) FT-Raman spectrum; (d) FT-IT spectrum; and (e) thermogravimetric analysis (TGA). | 2015-04-30 |
20150119399 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE - Disclosed are methods for stimulating or increasing β-cell replication or growth, e.g., for increasing insulin secretion, and methods of treating disorders such as diabetes, as well as related compositions and formulations. | 2015-04-30 |
20150119400 | METHODS FOR TREATING HCV - Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection. | 2015-04-30 |
20150119401 | Compositions and Methods for the Treatment of Nasal Conditions - The invention provides compositions and methods for treating nasal congestion. The provided compositions and methods utilize low concentrations of selective a-2 adrenergic receptor agonists. The compositions preferably include brimonidine. | 2015-04-30 |
20150119402 | ALPHA 7 NICOTINIC ACETYLCHOLINE ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF - The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of al nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on al nAChRs in a mammal by administering an effective amount of a compound of Formula I. | 2015-04-30 |
20150119403 | Mutant ROS Expression In Human Cancer - The invention provides the identification of the presence of mutant ROS protein in human cancer. In some embodiments, the mutant ROS are FIG-ROS fusion proteins comprising part of the FIG protein fused to the kinase domain of the ROS kinase. In some embodiments, the mutant ROS is the overexpression of wild-type ROS in cancerous tissues (or tissues suspected of being cancerous) where, in normal tissue of that same tissue type, ROS is not expressed or is expressed at lower levels. The mutant ROS proteins of the invention are anticipated to drive the proliferation and survival of a subgroup of human cancers, particularly in cancers of the liver (including bile duct), pancreas, kidney, and testes. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS polypeptides (e.g., a FIG-ROS(S) fusion polypeptide), probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The identification of the mutant ROS polypeptides enables new methods for determining the presence of these mutant ROS polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 2015-04-30 |
20150119404 | NOVEL COMPOUNDS - The invention relates to spiro derivatives, to the use of said derivatives in treating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation. | 2015-04-30 |
20150119405 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR - Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions. | 2015-04-30 |
20150119406 | TRICYCLIC PYRONE COMPOUNDS REDUCE AMYLOID BETA AGGREGATES - Tricyclic pyrone compounds having high oral bioavailability, excellent blood-brain barrier permeability, and low toxicity are presented. Administration of the compounds to Alzheimer's Disease transgenic models resulted in substantially reduced soluble and insoluble Aβ species in the brain without affecting general behavior and motor coordination. Furthermore, in addition to blocking the toxicity and formation of both intraneuronal and extracellular Aβ aggregates, the compounds also increase cellular cholesterol efflux, restore axonal trafficking, and enhance hippocampal synaptic plasticity. | 2015-04-30 |
20150119407 | SUBSTITUTED XANTHINE DERIVATIVES - This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentifylline and related compounds are beneficial. | 2015-04-30 |
20150119408 | Process For The Production Of An Enriched Natural Antioxidant Mixture From A Single Source Plant - A process for extracting antioxidants from a plant, including contacting a plant material from a guayusa plant for a first time with a solvent, thereby obtaining a first slurry, filtering said first slurry, thereby obtaining a first extract, contacting said plant material for a second time with said solvent, thereby obtaining a second slurry, filtering said second slurry, thereby obtaining a second extract, combining said first extract and said second extract, thereby generating an third extract containing at least antioxidants, xanthines, and amino acids, and substantially drying said third extract. | 2015-04-30 |
20150119409 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia, improves blood flow through peripheral blood vessels and therefore helps with blood circulation in the arms and legs (e.g. intermittent claudication), and the brain (hence its use in vascular dementia), venous disease, Peyronie's disease, neuropathic injuries, strokes, sickle cell disease, nausea and headaches in the mountains (altitude sickness), non-alcoholic steatohepatitis and alcoholic liver disease, fibrotic lesions induced by radiation therapy for breast cancer, cytokine release syndrome, cancer, type 1 diabetes and type 2 diabetes, asthma, bronchodilation, kidney diseases, renal protection, vascular ischemia, neuroprotection, vasodilation, Alzheimer's disease, dementia, stroke, and treatment of endometriosis. | 2015-04-30 |
20150119410 | BIOMARKERS OF RESPONSE TO NAE INHIBITORS - Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment. | 2015-04-30 |
20150119411 | INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS - Described herein are compounds, pharmaceutical compositions and methods for treating a respiratory syncytial virus infection in a subject, or for inhibiting replication of respiratory syncytial virus. | 2015-04-30 |
20150119412 | HETEROCYCLIC COMPOUND - A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: | 2015-04-30 |
20150119413 | TREATMENT OF POLYCYSTIC DISEASES WITH AN HDAC6 INHIBITOR - An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and β-catenin phosphorylation and/or acetylation while reducing bile duct β-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth. | 2015-04-30 |
20150119414 | STATIN AND OMEGA 3 FATTY ACIDS FOR REDUCTION OF APOLIPOPROTEIN-B LEVELS - A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. | 2015-04-30 |
20150119415 | METHODS AND COMPOSITIONS FOR IMPROVING GUT MICROBIOTA POPULATION - A method and a composition for improving gut micro biota structure, selectively increase a first gut microbiota population while simultaneously decrease a second gut micro biota population in a subject. The first gut micro biota population includes a short-chain fatty acid (SCFA)-producing bacterium and the second gut microbiota population includes an endotoxin-producing bacterium. | 2015-04-30 |
20150119416 | CARBOXAMIDE BIOISOSTERES OF OPIATES - A compound of formula I is disclosed. | 2015-04-30 |
20150119417 | METHODS FOR TREATING VISCERAL FAT CONDITIONS - Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion. | 2015-04-30 |
20150119418 | BICYCLIC COMPOUND - Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: | 2015-04-30 |
20150119419 | 6-AMINOISOQUINOLINE COMPOUNDS - 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided. | 2015-04-30 |
20150119420 | Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate - This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 2015-04-30 |
20150119421 | METHOD OF INHIBITING FLT3 KINASE - The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or FLT3 tyrosine kinase expression in a subject with a proliferative disease by administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound (CP-673,451) of Formula I: | 2015-04-30 |
20150119422 | SIMETHICONE FORMULATION - The present invention relates to solid pharmaceutical formulations based on simethicone and calcium phosphate and mannitol. | 2015-04-30 |
20150119423 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOCAL PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of moderate to severe pain, neuropathic pain, post herpetic neuralgia and rheumatic pains. | 2015-04-30 |
20150119424 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of epilepsy and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of convulsions, Lennox-Gastaut syndrome, migraine, bipolar disorder, post traumatic stress disorder. | 2015-04-30 |
20150119425 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE - The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. | 2015-04-30 |
20150119426 | MODULATORS OF THE RELAXIN RECEPTOR 1 - Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R | 2015-04-30 |
20150119427 | WATERBORNE TOPICAL COMPOSITIONS FOR THE DELIVERY OF AZELAIC ACID FOR TREATMENT OF SKIN CONDITIONS SUCH AS ACNE VULGARIS, ROSACEA, SEBORRHEIC DERMATITIS - A waterborne topical composition is designed specifically to address the treatment of acne vulgaris, rosacea, seborrheic dermatitis and other skin conditions. One composition contains effective amounts of essential components azelaic acid, niacinamide, and glycerin to create a rapidly penetrating and non-irritating compound. One composition contains effective amounts of essential components azelaic acid, niacinamide, and cyclodextran to create a rapidly penetrating and non-irritating compound. | 2015-04-30 |
20150119428 | TRANILAST COMPOSITIONS AND COCRYSTALS - Mew tranilast complexes and new tranilast cocrystals are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed. | 2015-04-30 |
20150119429 | Iron Chelators as HIV-1 Inhibitors - The present invention relates to chelator compounds for chelating metal ions. In particular, the present invention relates to (thio)semicarbazone compounds and (thio)hydrazone compounds, such as PpYeT and PpYaT, which are chelators for metal ions, including iron ions. Therapeutic use of such compounds and/or their metal ion complexes, includes methods for treating and inhibiting HIV-1 replication, particularly in HIV-1 infected cells. | 2015-04-30 |
20150119430 | Thiazole Compounds and Uses Thereof - The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis. | 2015-04-30 |
20150119431 | (R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel - (R)-Nifuratel is disclosed together with its use as bactericide and bacteriostatic agent as well as the pharmaceutical compositions containing the same; (R)-nifuratel has been surprisingly found to possess a better antimicrobial profile than either nifuratel racemate or (S)-nifuratel. A new procedure for the synthesis of both (R)-Nifuratel and (S)-Nifuratel is also disclosed. | 2015-04-30 |
20150119432 | ISOXAZOLINE COMPOUND COMPOSITION - The present invention relates to a composition comprising an isoxazoline compound, the isoxazoline compound being dispersed in a solid vehicle of one or more polymer compounds selected from cellulose polymers and vinyl polymers. | 2015-04-30 |
20150119433 | METHOD OF TREATING ACTINIC KERATOSIS ON THE FULL BALDING SCALP WITH INGENOL 3-(3,5-DIETHYLISOXAZOLE-4-CARBOXYLATE) - The invention relates to the topical treatment of actinic keratosis on the full balding scalp with ingenol 3-(3,5-diethylisoxazole-4-carboxylate). | 2015-04-30 |
20150119434 | Method for Topically Treating Actinic Keratosis with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) - The invention relates to the topical treatment of actinic keratosis with ingenol 3-(3,5-diethylisoxazole-4-carboxylate). | 2015-04-30 |
20150119435 | COMPOUNDS USEFUL FOR PROMOTING PROTEIN DEGRADATION AND METHODS USING SAME - The present invention includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the invention comprises a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. In other embodiments, the target protein contemplated within the invention comprises a posttranslational modified protein or intracellular protein. In yet other embodiments, compounds of the present invention are used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state. | 2015-04-30 |
20150119436 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing blood clotting disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of strokes in those with atrial fibrillation due to causes other than heart valve disease, and at least one additional risk factor for stroke (congestive heart failure, hypertension, age, diabetes, and prior stroke), and to prevent the formation of blood clots in the veins in adults operated to replace a hip or knee. | 2015-04-30 |
20150119437 | Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism - Methods for treating cognitive dysfunction by modulating brain energy metabolism using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed. | 2015-04-30 |
20150119438 | 3-PROPANOIC ACID IN CRYSTALLINE FORM AND METHODS FOR USE THEREOF - The present invention provides 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1H-pyrazol-3-yl}propanoicacid in crystalline form. The present invention further provides methods for treating disorders associated with DP | 2015-04-30 |
20150119439 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE - The invention provides saturated acyl guanidine compounds that inhibit F | 2015-04-30 |
20150119440 | EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF - Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described. | 2015-04-30 |
20150119441 | Modulators of ATP-Binding Cassette Transporters - Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention. | 2015-04-30 |
20150119442 | Biocide agents against marine woodborers - The present invention relates to biodegradable biocide agents against marine woodborers. In particular, the present invention relates to novel slow releasing biocide impregnating solutions against marine woodborers, and methods of creating anti marine woodborer environments. | 2015-04-30 |
20150119443 | METHOD OF THERAPY AND DIAGNOSIS OF ENDOTHELIAL DYSFUNCTION - The invention discloses a method of therapy of endothelial dysfunction, by administering microRNA let-7g to a subject in need, wherein the microRNA let-7g inhibits SMAD2 transcription factor from activation and translocation into nucleus, thereby decreasing monocyte cell adhesion, inflammation and thrombosis and increasing angiogenesis. | 2015-04-30 |
20150119444 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides - The present invention provides iRNA agents comprising at least one subunit of the formula (I): | 2015-04-30 |
20150119445 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides - The present invention provides iRNA agents comprising at least one subunit of the formula (I): | 2015-04-30 |
20150119446 | CUL4B AS PREDICTIVE BIOMARKER FOR CANCER TREATMENT - The current disclosure describes materials and methods for identifying subjects that would benefit from treatment with a DNA topoisomerase 1 inhibitor, based on the levels of cullin 4B gene, RNA and protein levels in the subject. The disclosure identifies CUL4B as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents. The current disclosure also identifies novel therapeutic agents that modulate the level of CUL4B expression, and sensitize a subject to treatment with a second therapeutic agent. | 2015-04-30 |
20150119447 | CLUSTERED SINGLE NUCLEOTIDE POLYMORPHISMS IN THE HUMAN ACETYLCHOLINESTERASE GENE AND USES THEREOF IN DIAGNOSIS AND THERAPY - The present invention relates to diagnostic and prognostic methods and kits for determining genetic predisposition for at least one AChE-associated disorder, as well for diagnosing, prognosing and monitoring said disorders. The methods of the invention are based on detection of specific SNPs that modulate the interaction of different miRNAs to AChE 3′-UTR. | 2015-04-30 |
20150119448 | RNA PRODUCTS AND USES THEREOF - The present invention relates to small RNAs, inhibitors thereof, inhibitors of enzymes producing thereof, and their use to modulate the response of a cell to a DNA damaging event. The invention concerns also a method to detect the presence or quantify DNA damage. | 2015-04-30 |
20150119449 | Methods and Compositions for Modulating MIR-204 Activity - The present invention provides compositions and methods for regulating insulin production. | 2015-04-30 |
20150119450 | COMPOSITIONS FOR USE IN TREATING OR DIAGNOSING BONE DISORDERS AND/OR CARDIOVASCULAR DISORDERS - Compositions of an inhibitor of a polynucleotide for use in treating or preventing bone disorders such as osteoporosis, osteopenia, bone fracture, bone cancer, as well as impaired bone homeostasis. Preferred compounds to be used in these medical interventions are antagonistic compounds, like nucleic acid molecules, directed against miR-31 and derivatives thereof. Also, methods for diagnosing and compositions for use in diagnosing bone disorders. Compounds to be employed in these diagnostic methods and uses include compounds such as miR-31. | 2015-04-30 |
20150119451 | TREATMENT OF INTERFERON REGULATORY FACTOR 8 (IRF8) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRF8 - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Interferon Regulatory Factor 8 (IRF8), in particular, by targeting natural antisense polynucleotides of Interferon Regulatory Factor 8 (IRF8). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of IRF8. | 2015-04-30 |
20150119452 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain. | 2015-04-30 |
20150119453 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis. | 2015-04-30 |
20150119454 | THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF - Described herein are well-defined cyclopentanols useful for treating glaucoma and ocular hypertension. | 2015-04-30 |
20150119455 | FORMULATION - Stable formulations of Olopatadine, methods of making such formulations and methods of treatment using such formulations are provided. | 2015-04-30 |
20150119456 | TRICYCLIC SULFONE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The invention provides tricyclic sulfone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 2015-04-30 |
20150119457 | ESSENTIAL OIL COMPOSITION FROM LEMON PEEL AS GROWTH PROMOTOR IN POULTRY INDUSTRY - The invention is referring to an essential oil from lemon peel useful as growth promoter in poultry, such composition comprises at least 16.84 to 46.12% of D-Limonene; 5.67 to 19.86% of y-Terpinene; 4.27 to 12.13% of Terpinolene; 4.60 to 14.75% of p-Ment-1-en-8-ol; among other components. The invention also refers to a poultry food supplement, which comprises 1 kg per metric ton of food from such composition of essential oil. | 2015-04-30 |
20150119458 | 4-((SUBSTITUTED PHENYL) DIFLUOROMETHYL) PHENOXY CARBOXYLIC ACID DERIVATIVE, AND PREPARATION METHOD AND USES THEREOF - The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof. | 2015-04-30 |
20150119459 | DERMAL-APPROPRIATE COMPOSITIONS AND METHODS OF USE - This invention relates to mild or weak acids and salt mixtures, such as Ascorbic acid, that when mechanically enhanced become dermal-appropriate, thereby allowing high levels of these compositions to be used in health-care, medical, pharmaceutical, nutraceutical and cosmoceutical products. | 2015-04-30 |
20150119460 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS - The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof. | 2015-04-30 |
20150119461 | TETRAHYDRO-ISOHUMULONE DERIVATIVES, METHODS OF MAKING AND USING - The present application provides novel tetrahydro-isohumulone (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPARγ, inhibit inflammation, and treat conditions associated with inflammation and conditions responsive to PPARγ modulation such as diabetes. | 2015-04-30 |
20150119462 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS - The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof. | 2015-04-30 |
20150119463 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS - The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof. | 2015-04-30 |
20150119464 | POLYUNSATURATED FATTY ACIDS FOR TREATMENT OF DEMENTIA AND PRE-DEMENTIA-RELATED CONDITIONS - Disclosed are compositions and methods for treating or preventing dementia and pre-dementia-related conditions and/or symptoms or characteristics of such conditions. | 2015-04-30 |
20150119465 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 2015-04-30 |
20150119466 | NANOSPHERE- HISTONE ACETYLTRANSFERASE (HAT) ACTIVATOR COMPOSITION, PROCESS AND METHODS THEREOF - The present invention is in relation to a composition including nanosphere and histone acetyltransferase (HAT) activator. The nanosphere is carbon nanosphere (CSP) which is intrinsically fluorescent and the HAT activator is N-(4-Chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide. The N-(4-Chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide is covalently conjugated with the carbon nanosphere. The present invention further relates to a process for obtaining a composition including carbon nanosphere and Histone acetyltransferase (HAT) activator [N-(4-Chloro-3-trifluoromethyl-phenyl)-2-n-propoxy-benzamide]. The composition is capable of crossing blood brain barrier and inducing histone acetylation in brain. Further, the composition is capable of increasing neurogenesis, as well as improving long-term memory formation. The composition manages pathological conditions to a subject in need thereof, such as aging-related, neurodegenerative diseases (Alzheimer's in particular), neurological disorders, depression or other kinds of diseases in which increased HAT activity, neurogenesis and/or memory improvement would benefit. | 2015-04-30 |
20150119467 | METHODS FOR TREATMENT OF PELVIC PAIN AND/OR COMORBID CONDITIONS - Methods, systems, devices, and medicaments are provided for locally administering to a pelvic-area organ or tissue structure in a patient at least one drug continuously or continually over a treatment period of 24 hours or more in an amount effective to achieve a therapeutic effect in another organ or tissue structure by means of shared or convergent pelvic afferent pathways. The methods systems, devices, and medicaments can be used in the treatment of IC/BPS, chronic pelvic pain, vulvodynia, orchialgia, urethral syndrome, dysparenia, chronic prostatitis, chronic pelvic pain, levator ani syndrome, irritative bowel syndrome, or a combination thereof. The drug may include anesthetic agents, analgesic agents, antispasmodic agents, antimuscarinic agents, and combinations thereof. The drug may be released from a drug delivery device or a sustained release composition deployed inside the bladder. | 2015-04-30 |
20150119468 | PROTECTION FROM CHEMICAL-INDUCED ACUTE LUNG INJURY - Methods are provided herein for treating an individual having a disease, disorder or condition affecting the lungs, wherein said disease, disorder, or condition of the lung is an acute lung injury. In specific embodiments, the acute lung injury is chemical induced acute lung injury (CIALI). In some embodiments, the methods are provided for treating or protecting a subject from chemical induced acute lung injury that include administering to the subject a therapeutically effective amount of a phosphatase located on chromosome 10 (PTEN) inhibitor such as N(9,10-dioxo-9,10-di-hydrophenanthren-2-yl)pivalamide (SF1670). In some embodiments, the method products a subject from CAILI or reduces CAILI that results from a subsequent exposure to a chemical that induces chemical induced acute lung injury. | 2015-04-30 |
20150119469 | Formulations and kit for biometric deposition of apatite on teeth - The invention proposes a kit and formulations for biomimetic deposition of apatite on teeth from a partially elastic shaped body comprising an envelope, whereby the shaped body a) comprises at least one mineralization matrix containing a gel that comprises water-soluble phosphates or phosphates that can be hydrolysed to form water-soluble phosphate ions and has a pH value of 2 to 8, optionally fluorides, and b) the at least one or a second mineralization matrix comprises a second gel having a pH value of 3.5 to 14 comprising calcium ions or compounds releasing calcium ions. Moreover, the method for producing the formulation and the use thereof for the deposition of apatite, in particular of needle-shaped fluorapatite crystallites, is claimed. Using the formulations according to the invention, it is feasible to deposit more than or equal to 1 μm apatite, in particular fluorapatite, on tooth surfaces in order to seal or brighten porous tooth surfaces. | 2015-04-30 |
20150119470 | COMPOUNDING AND EXTRUDING METHOD FOR PRODUCING STARCH SOFTGEL CAPSULES - The invention discloses a method for preparing starch softgel capsules, which, specifically, involves in the following three steps: 1, Extruding starch premix and gel solution into films respectively; 2, Forming composite starch film through co-extrusion method; 3, Processing the composite starch film into starch softgel capsules. | 2015-04-30 |
20150119471 | Preparation Process Of A Self-Reinforced Starch Composite Used To Produce Capsules - The invention discloses a technical process to prepare a self-reinforced starch composite used to produce capsules. This composite is made by uniformly mixing the matrix phase and the particulate reinforced phase at a proper proportion, the former being one or a combination of the starches selected from the group consisting of oxidized starch, cationic starch and esterified starch; and the latter, cross-linked starch or starch nanocrystals. This composite is processed into the forms of granules, films, or sheets by extrusion method and these different forms of the composite can be used to replace the gelatin as the raw material of capsules because its barrier property, processability, and mechanical properties are significantly improved. | 2015-04-30 |
20150119472 | MIXING AND EXTRUDING METHOD FOR PREPARING STARCH SOFTGEL CAPSULES - The invention discloses an extrusion method for preparing starch-based softgel capsules, which, specifically, includes the following 2 steps: 1, co-extruding the starch premix and gel solution to form composite starch film. 2, processing two composite starch films into starch-based softgel capsules by rotary die process. | 2015-04-30 |
20150119473 | Coating And Extruding Method For Producing Starch Softgel Capsules - The invention discloses a method for preparing starch-based softgel capsules, which, specifically, includes the following 2 steps: 1, Extrude the starch-based premixed material into starch-based extrusion film, 2, Apply the gel solution coating to the extrusion film to form composite starch film, 3) Process two composite starch films into starch-based softgel capsules by rotary die process. | 2015-04-30 |
20150119474 | COMPOSITION COMPRISING NORBIXIN AS AN ORANGE/RED PIGMENT - An orange/red coloring composition comprising norbixin as an orange/red pigment. Quillaja is present as a dispersing agent. It may be used in the manufacture of food and pharmaceutical products. | 2015-04-30 |
20150119475 | METHOD - The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity. | 2015-04-30 |
20150119476 | DEVELOPMENT, CHARACTERIZATION, AND USE OF AN ANTI-HYPUSINATED eIF5A ANTIBODY TO DIAGNOSE DIABETES - Provided herein is a comprehensive characterization of a novel polyclonal antibody (IU-88) that specifically recognizes the hypusinated eIF5A. The antibody IU-88 is useful for the investigation of eIF5A biology, for the development of assays recognizing hypusinated eIF5A, and for methods of treating conditions and diseases that involve the activity of hypusinated eIF5A. The antibody was used to determine that the levels of hypusinated eIF5A were elevated in the pancreatic tissues of patients diagnosed with Type 1 or Type 2 Diabetes. | 2015-04-30 |
20150119477 | METHODS AND SYSTEMS FOR CREATING AEROSOLS - Aerosols can be created by filament stretching and breaking of Newtonian and non-Newtonian fluids by applying a strain to and stretching the fluid. The fluid is stretched along a strain pathway and forms a fluid filament. The fluid filament is caused to break into droplets that can be harvested to form a mist or aerosol. Such a system for aerosol creation can include a pair of counter-rotating rollers that are positioned adjacent to each other that stretch the fluid or a pair of pistons that move toward and away from each other to stretch the fluid. | 2015-04-30 |
20150119478 | GAS-TO-LIQUID TECHNOLOGY - Gas-to-liquids processes for treating natural gas, including the steps of subjecting the natural gas to expansion through a flow restrictor so as to undergo cooling through the Joule Thomson effect. The processes then separate the resulting liquids from the remaining natural gas and processing the natural gas to form a synthesis gas. The synthesis gas is subjected to Fischer-Tropsch synthesis and the output from the Fischer-Tropsch synthesis is separated into a hydrocarbon product and an aqueous phase and the aqueous phase is steam stripped to extract the oxygenates which are then injected into the natural gas stream upstream of the flow restrictor. | 2015-04-30 |
20150119479 | SHAPE-MEMORY POLYMER WITH INTEGRAL RESISTIVE HEATING ELEMENT - A method of making a reconfigurable three-dimensional shape includes the following steps: (i) moving multiple print heads in three dimensions relative to a printing surface, where the print heads include a conductor print head and a polymer print head; (ii) depositing a conductive material from the conductor print head; and (iii) depositing a shape-memory polymer from the polymer print head. The depositing steps form a volumetric shape of a shape-memory polymer, capable of changing shape, with a conductive material capable of acting as a heating element integrally formed in the volumetric shape. The method can further include the steps of heating the shape-memory polymer above a transition temperature, changing the shape of the volumetric shape following the heating step, and then allowing the shape-memory polymer to cool below the transition temperature to fix the new volumetric shape. | 2015-04-30 |
20150119480 | Use of Gas Adsorbed to Moledular Sieves to Expand One-Component Foams upon Exposure to Moisture - A one-component moisture curing composition expands and cures under ambient conditions without the use of external blowing agents. The one-component moisture cure foam contains (1) a moisture curing polymer, (2) anhydrous molecular sieves that are able to adsorb atmospheric moisture to release adsorbed gases, optionally (3) catalyst compound(s) to accelerate the reaction between atmospheric moisture and the polymer, and optionally (4) other additives such as surfactants, fillers, adhesion promoters, pigments, water scavengers and foamable additives. | 2015-04-30 |
20150119481 | RESIN COMPOSITION FOR FOAMING CONTAINING BIODEGRADABLE RESIN, AND FOAM MANUFACTURED THEREFROM - There are provided a resin composition for foaming including a biodegradable resin and a foamed article made thereof. The resin composition for foaming according to the present invention includes an ethylene-vinyl acetate resin, a biodegradable polyester resin containing a monomer of a double bond compound, a cross-linking agent, a co-crosslinking agent, a filler, and a foaming agent. In the resin composition, the double bond in the biodegradable polyester resin can be chemically cross-linked to the ethylene-vinyl acetate resin by a cross-linking agent, so that a compatibility with the ethylene-vinyl acetate resin can be improved, processability (mold releasability) during a mixing and melting process can be improved, and a foaming property and a mechanical property of a foamed article can be remarkably improved. | 2015-04-30 |
20150119482 | METHOD TO ENHANCE CELL NUCLEATION DENSITY IN SOLID-STATE FOAMS - A method for creating a foam from a solid thermoplastic material is disclosed. The method includes heating a solid, noncellular thermoplastic material to a temperature greater than the material's glass transition temperature, and below the melting temperature, and then allowing the material to cool; after the material has cooled, saturating the cooled thermoplastic material with a non-reacting gas to provide a gas-saturated material; and heating the gas-saturated material below the melting temperature of the material so that the material remains a solid, and causes nucleation of bubbles, and creation of cells in the material. | 2015-04-30 |
20150119483 | FLAME RETARDANT POLY(SILOXANE) COPOLYMER COMPOSITIONS, METHODS OF MANUFACTURE, AND ARTICLES FORMED THEREFROM - A poly(siloxane) copolymer composition comprising: a first polymer comprising a first repeating unit, and a poly(siloxane) block unit, a second polymer different from the first polymer and comprising of bromine; and optionally, one or more third polymers different from the first polymer and second polymer; wherein siloxane units are present in the composition in an amount of at least 0.3 wt %, and bromine is present in the composition in an amount of at least 7.8 wt %, each based on the sum of the wt % of the first, second, and optional one or more third polymers; and further wherein an article molded from the composition has an OSU integrated 2 minute heat release test value of less than 65 kW-min/m | 2015-04-30 |
20150119484 | PARTICLES AND METHOD FOR PRODUCING PARTICLES - A method for producing particles, which contains: bringing a compressive fluid and a pressure plastic material into contact with each other to melt the pressure plastic material; and jetting a melt obtained by melting the pressure plastic material to form particles, wherein the jetting the melt is performed by a two-fluid nozzle or three-fluid nozzle. | 2015-04-30 |
20150119485 | METHOD FOR PRODUCING LOW-CHLORINE POLYBIPHENYL SULFONE POLYMERS - The present invention relates to a process for the production of low-chlorine-content polybiphenyl sulfone polymers, to the polybiphenyl sulfone polymers obtainable in this way, to polybiphenyl sulfone polymers with less than 800 ppm content of organically bonded chlorine, to thermoplastic molding compositions and moldings, fibers, films, membranes, or foams comprising the polybiphenyl sulfone polymers mentioned, and also to their use for the production of moldings, of fibers, of films, of membranes, or of foams. | 2015-04-30 |
20150119486 | CURABLE AQUEOUS LATEX INKS FOR INDIRECT PRINTING - The present disclosure provides a curable aqueous latex ink comprising a curable material, a photoinitiator and a polyester polymer, which is suitable for use in an indirect printing method. | 2015-04-30 |
20150119487 | EMULSIFIED UV CURABLE INKS FOR INDIRECT PRINTING - An emulsified UV curable ink comprising water, an amide gellant, a curable monomer, a photoinitiator; which is suitable for use in an indirect printing method. | 2015-04-30 |
20150119488 | POLYMERIZABLE RESINS CONTAINING A 1,3,5-HEXAHYDRO-1,3,5-TRIAZINE MOIETY, METHODS OF MAKING, AND DENTAL COMPOSITIONS CONTAINING THE SAME - Disclosed herein are methods of making polymerizable resins containing a 1,3,5-hexahydro-1,3,5-triazine moiety and dental compositions comprising such novel hydrolytic stable, polymerizable resins derived from 1,3,5-triacryloyl-hexahydro-1,3,5-triazine (TAT). | 2015-04-30 |
20150119489 | Thermoplastic Resin Composition Having Excellent Colorability and Mechanical and Physical Properties - Provided is a thermoplastic resin composition including: an acrylic graft copolymer (A), an aromatic vinyl-vinyl cyanide compound copolymer (B), a polyalkyl(meth)acrylate resin (C), and an acrylic compound-grafted silicon-based impact reinforcing agent (D). The thermoplastic resin composition can have excellent impact resistance and colorability with minimal or no deterioration of dimensional stability, molding processability, weather resistance and mechanical and physical properties. | 2015-04-30 |
20150119490 | DRY MORTAR AND EMULSION/DISPERSION BASED COMPOSITIONS - The presently disclosed and claimed inventive concept(s) related to a dry mortar composition or an emulsion/dispersion based composition having hydrophobically modified polymer compositions. The dry mortar composition or an emulsion/dispersion based composition comprises one or more polymer emulsions and/or redispersible powders, and one or more hydrophobic, and water-resistant or water-repellent additive. The emulsion/dispersion based composition can be used as a grout, a joint filler, a mastic, a pasty, textured plaster, tile adhesive, structure-latex based render, silicate render, fine dispersion render for skim coat, dispersion based tile grout, acrylate based render, latex-based primer, and colorized latex-based renders. | 2015-04-30 |
20150119491 | RUBBER COMPOSITION - A rubber composition includes a diene rubber containing at least a polybutadiene rubber produced by use of a rare earth element based catalyst; a carbon black in an amount of 10 to 99 parts by mass for 100 parts by mass of the diene rubber; and a dihydrazide compound in an amount of 0.1 to 5.0 parts by mass for the same. | 2015-04-30 |
20150119492 | TIRE TREAD - A tire, the tread of which comprises a rubber composition comprising at least:
| 2015-04-30 |
20150119493 | CARBINOL-TERMINATED POLYMERS CONTAINING AMINE - The present invention relates to diene polymers, wherein the diene polymers have, at the start of the polymer chains, tertiary amino groups of the formula (I) or (II) | 2015-04-30 |
20150119494 | METHOD OF MANUFACTURING COMPOSITE MATERIAL HAVING NANO STRUCTURE GROWN ON CARBON FIBER AND COMPOSITE MATERIAL HAVING NANO STRUCTURE MANUFACTURED USING THE SAME - Provided is a composite material having a nano structure grown on a carbon fiber with a high density. A method of manufacturing a composite material includes: modifying a surface of a carbon fiber by using an electron beam; growing a zinc oxide (ZnO) nano structure on the modified surface of the carbon fiber; and transferring the carbon fiber and the zinc oxide nano structure onto a polymer resin. | 2015-04-30 |
20150119495 | PREPARATION OF RUBBER COMPOSITION CONTAINING GRAPHITE PLATELETS AND TIRE WITH COMPONENT - Preparation of a rubber composition containing a dispersion of aligned exfoliated graphite platelets. Such rubber composition is prepared by a method comprised of a sequential combination of concentrated solvent or dry masterbatching of elastomer and exfoliated graphite platelets, followed by blending the masterbatch (after removing the solvent from the solvent based masterbatch) with additional elastomer(s) and then followed by processing the resulting rubber composition to align the dispersed exfoliated graphite platelets in a substantially parallel relation to each other. Such processing may comprise as least one of extrusion and calendaring the rubber composition. The invention further relates to a tire containing a component comprised of such rubber composition containing a dispersion of aligned exfoliated graphite platelets prepared by the aforesaid method. | 2015-04-30 |